Lung Cancer News and Research

Latest Lung Cancer News and Research

Sleep disturbances trigger autoimmune diabetes in men

Psychosocial factors, including sleep disturbance, increase the risk for autoimmune diabetes in adults, research indicates.

19 Oct 2012

Health benefits of fibrate add-on detected postprandially

Adding fenofibrate to statin treatment significantly improves postprandial triglyceride response over statin treatment alone in individuals with diabetes, show findings from a US study.

18 Oct 2012

Value of cranberries for UTI prevention called into question

Results from an updated systematic review suggest that the value of cranberry juice or capsule consumption for prevention of urinary tract infections is likely to be limited.

17 Oct 2012

Quitting smoking may improve HRQoL in advanced lung cancer

The health-related quality of life of patients with advanced-stage lung cancer is worsened if they smoke, report UK researchers.

17 Oct 2012

Brachyury variation may increase risk of chordoma

A genetic variation possessed by 40% of the population is associated with a five-fold increase in risk for developing chordoma, a cancer that strikes the bones of the skull and spine.

17 Oct 2012

Mixing mitochondrial DNA bad for physiology

Mice with mitochondrial DNA from two sources have abnormal physiology and cognition, researchers report in Cell.

16 Oct 2012

First analysis of IASLC malignant pleural mesothelioma database

The International Mesothelioma Interest Group (IMIG) staging system has been widely used, however, widespread concerns exist about the validity of the current malignant pleural mesothelioma (MPM) staging system.

16 Oct 2012

VeriStrat identifies NSCLC patients likely to respond to erlotinib

A study, published in the November 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, showed the plasma test VeriStrat can predict response but not survival benefit from erlotinib. The study was conducted on a subset of patients enrolled in the NCIC Clinical Trials Group, BR.21 phase III trial of erlotinib versus placebo in previously treated advanced non-small cell lung cancer patients.

16 Oct 2012

Fit elderly NSCLC patients should be considered for salvage targeted therapy

Until there are more validated biomarkers to direct treatment decisions, many physicians use patient age to decide what therapy to give their patients. Literature data report that older patients often go undertreated because of concerns for limited tolerance to toxic therapies.

16 Oct 2012

Male infertility linked to an enzyme complex issue

An enzyme complex present in sperm plasma membranes plays an important role in the overproduction of reactive oxygen species and oxidative stress in sperm with abnormal morphology, researchers have shown.

15 Oct 2012

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

15 Oct 2012

Contraceptive patch suppresses ovulation in obese, nonobese women

Use of a novel transdermal contraceptive patch suppresses ovulation in obese and nonobese women, research shows.

12 Oct 2012

One rule for one and one for another with diabetes

A joint consensus statement from the European Association for the Study of Diabetes and the American Diabetes Association encourages a shift in attitude over glycemic management in Type 2 diabetes.

12 Oct 2012

Perimetry identifies visual function changes in diabetic retinopathy

Perimetry could be adopted as a method to measure changes in visual function among individuals with diabetic retinopathy, show promising results from a prospective longitudinal study undertaken in Sweden.

12 Oct 2012

Nelfinavir slows progress of HER2-positive tumor cells

After screening more than 2,300 drugs for their ability to halt the growth of breast cancer cells, Johns Hopkins researchers have discovered that the anti-HIV drug nelfinavir slows the progress of HER2-positive tumor cells, even if they are resistant to other breast cancer drugs.

12 Oct 2012

Dana-Farber expert offers tips to reduce risk of breast cancer

According to the American Cancer Society, about one in eight women will develop breast cancer in her lifetime. This year, nearly 40,000 women in the United States will die from the disease.

12 Oct 2012

Tomatoes every day may keep stroke at bay

Regular consumption of tomatoes and other lycopene-rich fruits and vegetables may help reduce a man’s risk for stroke, suggest study findings.

11 Oct 2012

MD Anderson, Methodist create new 3D model for lung cancer research

A new technique that allows scientists to grow lung cancer cells in three dimensions could accelerate discoveries for a type of cancer that has benefited little from scientific research over the last several decades.

11 Oct 2012

NCI identifies method by which cancerous mRNA escapes the body's safeguards

In innumerable spy movies, the hero or a villain imprints a key in clay in order to later make an exact copy. In the body, the clay is messenger RNA, or mRNA, which imprints a gene and transfers the plans to a ribosome, where the mRNA's code is manufactured into a protein - the shady shop where the clay imprint becomes a key.

11 Oct 2012

NewLink Genetics to launch algenpantucel-L Phase 3 study in pancreatic cancer

NewLink Genetics Corporation announces launching of an open-label, randomized, multi-institutional Phase 3 study in patients with borderline resectable or locally advanced unresectable pancreatic cancer.

10 Oct 2012